- Aktuelle Publikationsliste von Aram Prokop
Full paper
1. Prokop, A., Wieder, T., Sturm, I., Eßmann, F., Seeger, K., Wuchter, C., Ludwig, W.-D., Henze, G., Dörken, B., and Daniel, P.T., Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2- ratio and loss of spontaneous caspase-3 processing in vivo, Leukemia, 2000, 14: 1606-1613.
2. Wieder, Th., Eßmann, F., Prokop, A., Schmelz, K., Schulze-Osthoff, K., Beyaert, R., Dörken, B., and Daniel, P. T.; Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3, Blood, 2001,97: 1378- 1387.
3. Wieder, T., Prokop, A., Bagci, B., Essmann, F., Bernicke, D., Schulze-Osthoff, K., Dörken, B., Schmalz, H.G., Daniel, P.T. and Henze, G.; Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary leukemic lymphoblasts. Leukemia, 2001, 15: 1735-42.
4. Prokop, A., Wrasidlo, W., Lode, L., Herold, R., Lang, F., Henze, G., Dörken, B., Wieder, T. and Daniel, P. T., Induction of apoptosis by enediyne antibiotic calicheamicin JII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene, 2003, 22 (57): 9107-20.
5. Schlawe, D., Majdalani, A., Velcicky, J., Heßler, E., Wieder*, T., Prokop, A.*, and Schmalz, H-G.*. Iron-containing nucleoside analogs with pronounced apoptosis-inducing activity. Angewandte Chemie, 2004, 116, 1763-1766
6. Velcicky, J., Lanver, A., Lex, J., Prokop, A.*, Wieder, T.*, Schmalz, H.-G.*. Transition-Metal-Mediated Synthesis of Novel Carbocyclic Nucleoside Analogues with Antitumoral Activity. Chem. Eur. J. 2004, 10, 5087-5110.
7. Diller, R. A., Riepl, H. M., Rose, O. Frias, C., Henze, G. and Prokop, A., Synthesis of demethylxanthohumol, a new potent apoptosis inducing agent from hops, Chemistry & Biodiversity, 2005, 2: 1331-1338
8. James, P., Prokop, A.*, Neudörfl, J., Eißmann, M., Jesse, P., Henze, G., and Schmalz*, H.-G., Enantioselective Synthesis of Ferrocenyl Nucleoside Analogs with Apoptosis-Inducing Activity, Org. Lett., 2006, 13: 2763-2766
9. Shults, E.E., J. Velder, J., Schmalz, H.-G., Chernov, S.V., Rubalova, T.V., Gatilov, Y.V., Henze, G., Tolstikov, G.A., and Prokop, A., Gram-scale synthesis of pinusolide and its antileukemic potential, BMCL, 2006, 16: 4228 - 4232
10. Diller, R.A., Riepl, H.M., Rose, O., Frias, C., Henze, G., and Prokop, A., Ability of Prenylflavanones present in hops to induce apoptosis in a mitochondrial dependent manner in human Burkitt Lymphoma cell line BJAB, Plant. Med., 2007, 73: 755-761
11. Seifert, G., Jesse, P., Laengler, A., Reindl, T., Lüth, M. Lobitz, S., Henze, G., Prokop*, A., Lode* H. N. Molecular mechanisms of Mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro, Cancer Letters, 2008, 264: 218-228
12. Gansäuer, A., Winkler, I., Worgull, D., Lauterbach, T., Franke, D., Selig, A., Wagner, L., Prokop, A.; Carbonyl-substituted Titanocenes: A novel class of cytostatic compounds with high antitumor and antileukemic activity. Chemistry Eur. J., 2008,14: 4160-4163
13. Meggers, E., Atilla-Gokcumen, G.E., Gründler, K., Frias, C., and Prokop, A.; Inert Ruthenium Half-Sandwich Complexes with Anticancer Activity; Dalton Transactions, 2009, 48:10882-10888
14. Nicolaus, N., Strauss, S., Neudörfl, J.M., Prokop, A., Schmalz, H.G.; A [2 + 2 + 2]-cycloaddition approach toward 6-oxa-allocolchicinoids with apoptosis-inducing activity. Org Lett.; 2009,11(2):341-344
15. Ott, I., Qian, X., Xu, Y., Vlecken, D.H., Marques, I.J., Kubutat, D., Will, J., Sheldrick, W.S., Jesse, P., Prokop, A., Bagowski, C.P.; A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J Med Chem., 2009, 53: 763-770
16. Dobroschke, M., Geldmacher, Y., Ott, I., Harlos, M., Kater, L., Wagner, L., Gust, R., Sheldrick, W.S., Prokop, A.; Cytotoxic rhodium(III) and iridium(III) polypyridyl complexes: structure-activity relationships, antileukemic activity, and apoptosis induction. ChemMedChem.; 2009, 4(2):177-187
17. Jesse, P., Mottke, G., Eberle, J., Seifert, G., Henze, G., Prokop, A.; Apoptosis-inducing activity of Helleborus niger in ALL and AML. Pediatr Blood Cancer.; 2009, 52(4):464-469
18. Bieda, R., Ott, I., Dobroschke, M., Prokop, A., Gust, R., Sheldrick, W.S.; Structure-activity relationships and DNA binding properties of apoptosis inducing cytotoxic rhodium(III) polypyridyl complexes containing the cyclic thioether [9]aneS(3). J Inorg Biochem., 2009, 103(5):698-708
19. Bernt, K.M., Prokop, A., Huebener, N., Gaedicke, G., Wrasidlo, W., Lode, H.N.; Eradication of CD19+ leukemia by targeted calicheamicin θ. Bioconjug Chem.; 2009, 20(8):1587-1594
20. Meggers, E., Atilla-Gokcumen, G.E., Gründler, K., Frias, C., Prokop, A.; Inert ruthenium half-sandwich complexes with anticancer activity. Dalton Trans.; 2009, (48):10882-10888
21. Lee. S.Y., Peckermann, I., Abinet, E., Okuda, J., Henze, G., Prokop, A.; The rare-earth yttrium complex [YR(mtbmp)(thf)] triggers apoptosis via the extrinsic pathway and overcomes multiple drug resistance in leukemic cells. Med Oncol. 2010
22. Rubbiani, R., Kitanovic, I., Alborzinia, H., Can, S., Kitanovic, A., Onambele, L.A., Stefanopoulou, M., Geldmacher, Y., Sheldrick, W.S., Wolber, G., Prokop, A., Wölfl, S., Ott, I.; Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. J Med Chem.; 2010, 53(24):8608-8618
23. Lee, S.Y., Hille, A., Frias, C., Kater, B., Bonitzki, B., Wölfl, S., Scheffler, H., Prokop, A., Gust, R.; [NiII(3-OMe-salophene)]: a potent agent with antitumor activity. J Med Chem.; 2010, 53(16):6064-6070
24. Bieda, R., Dobroschke, M., Triller, A., Ott, I., Spehr, M., Gust, R., Prokop, A., Sheldrick, W.S.; Cell-selective, apoptosis-inducing rhodium(III) crown thiaether complexes. ChemMedChem.; 2010, 5(7):1123-1133
25. Nicolaus, N., Zapke, J., Riesterer, P., Neudörfl, J.M., Prokop, A., Oschkinat, H., Schmalz, H.G.; Azides derived from colchicine and their use in library synthesis: A practical entry to new bioactive derivatives of an old natural drug. ChemMedChem.; 2010, 5(5):661-665
26. Franke, J.C., Plötz, M., Prokop, A., Geilen, C.C., Schmalz, H.G., Eberle, J.; New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue. Biochem Pharmacol., 2010; 79(4):575-586.
27. Splith, K., Hu, W., Schatzschneider, U., Gust, R., Ott, I., Onambele, L.A., Prokop, A., Neundorf, I.; Protease-activatable organometal-Peptide bioconjugates with enhanced cytotoxicity on cancer cells. Bioconjug Chem., 2010; 21(7):1288-1296.
28. Mulcahy, S.P., Gründler, K., Frias, C., Wagner, L., Prokop, A., Meggers, E.; Discovery of a strongly apoptotic ruthenium complex through combinatorial coordination chemistry. Dalton Trans., 2010; 39(35): 8177-8182.
29. Kater, B., Hunold, A., Schmalz, H.G., Kater, L., Bonitzki, B., Jesse, P., Prokop, A.; Iron containing anti-tumoral agents: unexpected apoptosis-inducing activity of a ferrocene amino acid derivative. J Cancer Res Clin Oncol., 2010
30. Lee, S.Y., Hille, A., Kitanovic, I., Jesse, P., Henze, G., Wölfl, S., Gust, R., Prokop, A. [Fe(III)(salophene)Cl], a potent iron salophene complex overcomes multiple drug resistance in lymphoma and leukemia cells. Leuk Res., 2010
31. He, X., Gong, L., Kräling, K., Gründler, K., Frias, C., Webster, R.D., Meggers, E., Prokop, A.; Xia H.; Unusual eta2-allene osmacycle with apoptotic properties. Chembiochem., 2010; 11(11): 1607-1613.
32. Onambele, L.A., Koth, D., Czaplewska, J.A., Schubert, U.S., Görls, H., Yano, S., Obata, M., Gottschaldt, M., Prokop, A.; Mitochondrial mode of action of a thymidine-based cisplatin analogue breaks resistance in cancer cells. Chemistry., 2010; 16(48):14498-14505.
33. Kausch-Busies, N., Neudörfl, J.M., Prokop, A., and Schmalz, H.G.; Synthesis and First Biological Evaluation of an Iron-Containing HETE-Analogue. Eur. J.Org. Chem. 2011, 1133-1139.
34. Kausch-Busies, N., Neudörfl, J.-M., Wefelmeier, P., Prokop, A., Kühn, H., Schmalz, H.-G.; Stereoselective Synthesis and Biological Evaluation of Ferrocene-Containing, HETE-Analogs. Eur. J. Org. Chem., 2011, 24: 4634-4644.
35. Geldmacher, Y., Rubbiani, R., Wefelmeier, P., Prokop, A., Ott, I., Sheldrick, W.S.; SynthesisandDNA-bindingpropertiesof apoptosis-inducingcytotoxic half-sandwichrhodium (III)complexeswithmethyl-substituted polypyridyl ligands. Journal of Organometallic Chemistry, 2011, 696: 1023-1031
36. Geldmacher, Y., Kitanovic, I, Alborzinia, H., Bergerhoff, K., Rubbiani, R., Wefelmeier, P., A. Prokop, R. Gust, I. Ott, S. Wölfl, W. S. Sheldrick; Cellular Selectivity and Biological Impact of Cytotoxic Rhodium(III) and Iridium(III) Complexes Containing Methyl-substituted Phenanthroline Ligands. ChemMedChem, 2011, 6: 429-439.
37. Kater, L., Claffey, J., Hogan, M., Jesse, P., Kater, B., Strauss, S., Tacke, M., A. Prokop; A.; The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells. Toxicol In Vitro, 2011, 26(1):119-124.
38. Streiter, M., Malecki, M., Prokop, A., Schildgen, V., Lüsebrink, J., Guggemos, A., Wisskirchen, M., Weiss, M., Cremer, R., Brockmann, M., Schildgen, O.; Does human bocavirus infection depend on helper viruses? A challenging case report. Virol J., 2011; 8:417.
39. Wild, A., Babiuch, K., König, M., Winter, A., Hager, M.D., Gottschaldt, M., Prokop, A., Schubert, U.S.; Synthesis of a glycopolymeric Pt(II) carrier and its induction of apoptosis in resistant cancer cells. Chem Commun (Camb), 2012
40. Geldmacher, Y., Splith, K., Kitanovic, I., Alborzinia, H., Can, S., Rubbiani, R., Nazif, M.A., Wefelmeier, P., Prokop, A., Ott, I., Wölfl, S., Neundorf, I., Sheldrick, W.S.; Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their organoiridium(III) and trichloridorhodium(III) counterparts. J Biol Inorg Chem., 2012,17(4): 631-646
41. Köster, S. D., Alborzinia, H., Can, S., Kitanovic, I., Wölfl, S., Rubbiani, R., Ott, I., Riesterer, P., Prokop, A., Merz, K., Metzler-Nolte, N.; A spontaneous gold(I)-azide alkyne cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line; Chem. Sci., 2012, 3: 2062-2072.
42. Sitnikov, N., Velder, J., Abodo, L., Cuvelier, N., Neudörfl, J., Prokop, A., Krause, G., Fedorov, A. Y., Schmalz, H.-G.; Total Synthesis of Indole-derived Allocolchicine Analogs Exhibiting Strong Apoptosis-inducing Activity; Chem. Eur. J., 2012, 18: 12096-12102.
43. Termath, A. O., Ritter, S., König, M., Kranz D. P., Neudörfl, J.- P., Prokop, A.*, Schmalz, H.- G.; Sythesis of Oxa-B-Ring Analogs of Colchicine through Rh- Catyzed Intramolecular (5+2) Cycloaddition; European Journal of Organic Chemistry, 2012, 24: 4501–4507
44. Beulertz, J., Bloch, W., Prokop, A., Baumann, F.T.; Therapeutische Rahmenbedingungen von Bewegungsprogrammen in der pädiatrischen Onkologie. Erste Erfahrungen aus der Praxis. Deutsche Zeitschrift für Onkologie. 2012; 44: 162-166.
45. Navakovski de Oliveira, K., Andermark, V., von Grafenstein, S., Onambele, L. A., Dahl, G., Rubbiani, R., Wolber, G., Gabbiani, C., Messori, L., Prokop, A., Ott, I.; Butylin (IV) Benzoates: Inhibition of Thioredoxin reductase, Tumor Cell Growth Inhibition, and Interactions with Proteins; Chem Med Chem, 2013, 2: 256- 264
46. Pfeiffer, H., Dragoun, M., Prokop, A., Schatzschneider, U.; Biological Activity of Molybdenum(II) Allyl Dicarbonyl Complexes with N- N Coligands of Variable Aromatic Surface Area on Adherent and Non- adherent Human Cancer Cells, Zeitschrift für anorganische und allgemeine Chemie, 2013, (8-9): 1568–1576
47. Beulertz, J., Bloch, W., Prokop, A., Baumann, F.T.; Specific deficit analyses in motor performance and quality of life of pediatric cancer patients--a cross-sectional pilot study; Pediatr Hematol Oncol., 2013, 30(4): 336-347.
48. Oehninger, L., Küster, L.N., Schmidt, C., Muñoz-Castro, A., Prokop, A., Ott, I.; A Chemical–Biological Evaluation of Rhodium(I) N-Heterocyclic Carbene Complexes as Prospective Anticancer Drugs. Chem. Eur. J., 2013
49. Hirschhäuser, C., Velcicky, J., Schlawe, D., Hessler, E., Majdalani, A., Neudörfl, J.M., Prokop, A.*, Wieder, T., Schmalz, H.-G.; Nucleoside Analogues with a 1,3-Diene--Fe(CO)3 Substructure: Stereoselective Synthesis, Configurational Assignment, and Apoptosis-Inducing Activity.; Chemistry. 2013, 39: 13017-13029
50. Beulertz, J., Bloch, W., Prokop, A., Baumann, F.T.; Zielgerichtete und individualisierte Bewegungstherapie in der pädiatrischen Onkologie – ein Pilotprojekt. Monatsschrift Kinderheilkunde. 2013; 4: 330-335.
51. Beulertz, J., Bloch, W., Prokop, A., Baumann, F.T. Specific deficit analyses in motor performance and quality of life of pediatric cancer patients – a controlled cross-sectional trial. Pediatric hematology/oncology. 2013; 30(4): 336-47.
52. Kuznetsova, N. R., Svirshchevskaya, E. V., Sitnikov, N. S., Abodo, L., Sutorius, H., Zapke, J., Velder, J., Thomopoulou, P., Oschkinat, H., Prokop, A., Schmalz, H.-G., Fedorov,Y. A., Vodovozova, E. L.; Lipophilic prodrugs of a triazole-containing colchicine analogue in liposomes: Biological effects on human tumor cells. Russ. J. Bioorg. Chem., 2013, 39: 543-552
53. Sitnikov, N. S., Kokisheva, A. S., Fukin, G. K., Neudörfl, J.-M., Sutorius, H., Prokop, A., Fokin, V. V., Schmalz, H.-G., and Fedorov, A.Y.; Synthesis of Indole-Derived Allocolchicine Congeners through Pd-Catalyzed Intramolecular C-H Arylation Reaction. Eur. J. Org. Chem., 2014, 29, 6481–6492
54. Serebryanskaya, T.V., Lyakhov, A. S., Ivashkevich, L.S., Schur, J., Frias, C., Prokop, A., and Ott. I.*; Gold(I) thiotetrazolates as thioredoxin reductase inhibitors and antiproliferative agents. Dalton Transactions, 2014
55. Gansäuer, A., Okkel, A., Schwach, L., Wagner, L., Selig, A., Prokop, A.; Triazol-substituted titanocenes by strain-driven 1,3-dipolar cycloadditions, BEILSTEIN J. ORG. CHEM., 2014, 10, 1630-1637
56. De Oliveira, K. N., Andermark, V., Onambele, L. A., Dahl, G., Prokop, A. and Ott, I.; Organotin complexes containing carboxylate ligands with maleimide and naphthalimide derived partial structures: TrxR inhibition, cytotoxicity and activity in resistant cancer cells;, EUR. J. MED. CHEM., 2014, 87, 794-800
57. Beulertz, J., Bloch, W., Rustler, V., Herich, L., Streckmann, F., Fitzen, C., Prokop, A., Baumann, F.T.; Ankle Dorsiflexion Range of Motion and Gait in childhood cancer patients. Cancer Nursing, 2014,
58. Hoell, J.I., Gombert, M., Ginzel, S., Loth, S., Landgraf, P., Käfer, V., Streiter, M., Prokop, A., Weiss, M., Thiele, R., and Borkhardt, A.; Constitutional mismatch repair-deficiency and whole-exome sequencing as the means of the rapid detection of the causative MSH6 defect. Klinische Pädiatrie 2014, 226(6-7): 357-61
59. Beulertz, J., Bloch, W., Prokop, A., Herich, L., Baumann, F.T.; The effect of a six-month therapeutic exercise program on motor performance in childhood cancer patients. Study protocol of the ESCiMo-Study. BMC Pediatrics, 2014
60. Abodo Onambele, L., Riepl. H., Fischer, R., Pradel, G., Prokop, A.*, Aminake, M. N.; Synthesis and evaluation of the antiplasmodial activity of tryptanthrin derivatives. International Journal for Parasitology, 2015, Drugs and drug resistance 5: 48 - 57
61. Yadav, D.B., Taleli, L., van der Westhuyzen, A.E., Fernandes, M.A., Dragoun, M., Prokop, A., Schmalz, H.-G., de Koning , C.B., and Willem A. L. van Otterlo, W.A.L.; Synthesis of diverse 6-oxa-allocolchicinoids by a Suzuki-Miyaura coupling, acid-catalyzed-intramolecular-transacetalization strategy. European Journal of Organic Chemistry, 2015
62. Prinz, C., Lohmann, G., Vasyutina, E., Romanski, S., Hirschhäuser, C., Mayer, P., Frias, C., Hallek, M., Schmalz, H.-G., Prokop, A., Mougiakakos, D., Herling, M., Schrader, A., and Herling, C. D.; Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. Molecular Cancer, 2015
63. Sitnikov, N.S., Sinzov, A.V., Allegro, D., Barbier, P., Onambele, L.A., Prokop, A., Schmalz, H.-G., and Fedorov, A.Y.; Synthesis of indole-derived allocholchicine congeners exhibiting pronounced anti proliferative and apoptosis inducing properties. MedChemCommun, 2015
64. Beulertz, J. Rustler, V., Prokop, A. und Baumann, F.; Nebenwirkungen und Spätfolgen in der pädiatrischen Onkologie – Potentiale der Bewegungstherapie. Onkologische Pharmazie, 2016, Nr. 1/2016 S. 10 – 14
65. Beulertz, J., Bloch, W., Prokop, A., Rustler, V., Fitzen, C., Herich, L., Streckmann, F., Baumann, F.T. Limitations in Ankle Dorsiflexion Range of Motion, Gait, and Walking Efficiency in Childhood Cancer Survivors. Cancer Nurs., 2016 Mar-Apr;39(2): 117-24.
66. Beulertz, J., Prokop, A., Rustler, V., Bloch, W., Felsch, M., Baumann, F.T.
Effects of a 6-Month, Group-Based, Therapeutic Exercise Program for Childhood Cancer Outpatients on Motor Performance, Level of Activity, and Quality of Life.
Pediatr Blood Cancer, 2016, 63(1):127-32
67. Prokop, A., Czaplewska, J. A., Dobroschke, M., König, M., Wild, A., Thorwirth, R., Schulze, B., Babiuch, K., Pretzel, D., Schubert, U. S., and Gottschaldt, M.; Iridium(III) Complexes of Terpyridine- and Terpyridine-Analogous Ligands Bearing Sugar Residues and Their in vitro Activity. Eur. J. of Inorganic Chem., 2016, 3480-88
68. Streciwilk, W., Terenzi, A., Misgeld, R., Frias, C., Jones, P. G., Prokop, A., Keppler, B., Ott, I.; Metal NHC Complexes with Naphthalimide Ligands as DNA-Interacting Antiproliferative Agents. Chem.Med.Chem., 2017, 12 (3): 214 - 225
69. Schmidt,C., Karge, B., Misgeld, R., Prokop, A., Franke, R., Brçnstrup, M., and Ott, I.; Gold(I) NHC Complexes: Antiproliferative Activity, Cellular Uptake, Inhibition of Mammalian and Bacterial Thioredoxin Reductases and Gram-Positive Directed Antibacterial Effects. Eur. J. Chem., 2017, 23 (8): 1869 - 1880
70. Schmidt,C., Karge, B., Misgeld, R., Prokop, A., Brçnstrup, M., and Ott, I.; Biscarbene gold(I) complexes: structure-activity-relationships regarding antibacterial effects, cytotoxicity, TrxR inhibition and cellular bioavailability. Med. Chem. Commun., 2017, 8 (8): 1681 - 1689
71. König, M., Siegmund, D., Raszeja, L.J., Prokop, A., and Metzler-Nolte, N.; Resistance-breaking profiling and gene expression analysis on an organometallic ReI-phenanthridine complex reveal parallel activation of two apoptotic pathways. Journal of Medicinal Chemistry, 2017, 9: 173-180
72. Rustler, V., Prokop, A., Baumann, F., Streckmann, F., Bloch, W. , and Däggelmann, J.; Whole-body vibration training designed to improve functional impairments after pediatric inpatient anticancer therapy: A pilot study. Pediatr. Phys. Ther, 2018, 30 (4): 341 – 349
73. Dragoun, M., Günther, T., Frias, C., Berkessel, A., Prokop, A.; Metal-free salan-type compound induces apoptosis and overcomes multidrug resistance in leukemic and lymphoma cells in vitro. Journal of Cancer Research and Clinical Oncology, 2018, 144 (4): 685 - 695
74. Schmidt, C., Albrecht, L., Balasupramaniam, S., Misgeld, R., Karge, B., Brönstrup, M., Prokop, A., Baumann, K., Reichl, S., and Ott, I.; A gold(I) biscarbene complex with improved activity as TrxR inhibitor and cytotoxic drug: comparative studies with different gold metallodrugs. Metallomics, 11(3): 533-545, 2019
75. Krull, K., Kunstreich, M., Bronsema, A., Bleckmann, K., Classen, C.-F., Erdlenbruch, B., Jorch, N., Kolb, R., Leipold, A., Prokop, A., Scheurlen, W., Steinbach, D., Weber, C., Klasen-Sansone, J., Klee, D., Escherich, G., Moericke, A., Schrappe, M., Borkhardt, A., and Kuhlen, M.; Osteonecrosis in children with ALL at initial diagnosis and prior to any chemotherapy. Leukemia & Lymphoma, 60(1):78-84, 2019
76. Zernikow, B., Maaßen, K., Hübner-Möhler, B., Wager, J., Paulussen, M., Lassay, L., Jorch, N., Dilloo, D., Schneider, D., Janßen, G., Oommen, P.T., Kuhlen, M., Brune, T., Wieland, R., Kremens, B., Längler, A., Prokop, A., Niehues, T., MD B. Köster, B., Rose, M., Baumann-Köhler, M., Irnich, M., Kiener, R., Sinha, K., Wolfe, J., and Schmidt, P.; Specialized pediatric palliative care services for children dying from cancer:
developments of symptom management and quality of care over a 10-year period. Journal of Palliative Medicine, 33(3): 381-391, 2019
77. Oschwald, V., Prokop, A., Böhme, J., Gressler, N., Harscheidt, F., Maas, V., Bloch, W., Baumann, F.T., Julia Daeggelmann, J.; Limited walking abilities and impaired ankle dorsiflexion function in children after intense cancer treatment. Klinische Pädiatrie, 231: 142-149, 2019
78. Grau, M., Jerke, M., Nader, E., Schenk, A., Renoux, C., Collins, B., Dietz, T., Bizjak, D. A., Joly, P., Bloch, W., Philippe Connes, P., and Prokop, A.; Effect of acute exercise on RBC deformability and RBC nitric oxide synthase signalling pathway in young sickle cell anaemia patients. Scientific reports, 9: 11813, 2019
79. Grau, M., Nader, E., Jerke, M., Schenk, A., Renoux, C., Dietz, T., Collins, B., Bizjak, D., Joly, P., Bloch, W., Prokop, A., Connes, P.; Impact of a six-week training program on ventilatory efficiency, red blood cell rheological parameters and red blood cell nitric oxide signaling in young sickle cell anemia patients. Journal of Clinical Medicine, 8: 2155, 2019
80. Kunz, JB., Lobitz, S., Grosse, R., Oevermann L., Hakimeh, D., Jarisch, A., Cario, H., Beier, R., Schenk, D., Schneider, D., Groß‐Wieltsch, U., Prokop, A., Heine, S., Khurana, C., Erlacher, M., Dürken, M., Linke, C., Frühwald, M., Corbacioglu, S., Claviez, A., Metzler, M., Ebinger, M., Full, H., Wiesel, T., Eberl, W., Reinhard, H., Tagliaferri, L., Allard, P., Karapanagiotou‐Schenkel, I., Rother, L.-M., Beck, D., Le Cornet, L., Kulozik, A.E., German Sickle Cell Disease Registry; Sickle cell disease in Germany: Results from a national registry. Pediatr Blood Cancer, 67(4):e28130. 2019
81. Oschwald, V., Prokop, A., Boehme, J., Gressler, N., Harscheidt, F., Maas, V., Bloch, W., Baumann, FT., Daeggelmann, J.; Limited Walking Abilities and Impaired Ankle Dorsiflexion Function in Children After Intense Cancer Treatment. Klin. Padriatr., 231: 142-149, 2019
82. Basova, S., Wilke, N., Koch, J. C., Prokop, A., Berkessel, A., Pradel, G., and Ngwa, C. J.; Organoarsenic Compounds with In Vitro Activity against the Malaria Parasite Plasmodium falciparum. Biomedicines, 8(8):260. 2020
83. Hopff, S.M., Onambele, L.A., Brandenburg, M., Berkessel, and Prokop, A.; Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro. Bioorganic Chemistry, 104:104193. 2020
84. Däggelmann, J., Prokop, A., Lösse, V., Maas, V., Otten, S., Bloch, W.; Indoor Wall Climbing with Childhood Cancer Survivors: An Exploratory Study on Feasibility and Benefits. Klin. Padiatr., 232: 159-165. 2020
85. Rössler, R., Baselga, E., Davila, V., Celis, V., Diociaiuto, A., Hachem, ME., Mestre, S., Häberli, D., Prokop, A., Hanke, C., Loichinger, W., Quere, I., Baumgartner, I., Niemeyer, C., Kapp, F.; Severe adverse events during sirolimus “off label” therapy for vascular anomalies. Pediatric Blood & Cancer. 68(8): e28936. 2020
86. Daeggelmann, J., Prokop, A., Loesse, V., Otten, S., Maas, V., Bloch, W., Oschwald, V.; Implementing sustainable physical activity opportunities in pediatric oncology – Five-year experience of a group-based exercise program. German Journal of Sports Medicine, 72: 223-229. 2021
87. Hopff, S.M., Onambele, L.A., Brandenburg, M., Berkessel, A., Prokop, A.; Sensitizing multidrug-resistant leukemia cells to common cytostatics by an aluminium-salen complex that has high-apoptotic effects in leukemia, lymphoma and mamma carcinoma cells. Biometals, 34(2):211-220. 2021
88. Daeggelmann, J., Otten, S., Prokop, A., Maas, V., Streckmann, F., Bloch, W., Oschwald, V.; Feasibility of a combined supervised and home-based whole-body vibration intervention in children after inpatient oncological treatment. Sport Sci Health, 17:1025–1033 2021
89. Daeggelmann, J., Otten, S., Lösse, V., Prokop, A., Maas, V., Waltz, T., Jung, L., Bloch, W., Oschwald, V.; Bewegungsförderung während der kinderonkologischen Akuttherapie - Erfahrungen aus vier Jahren stationärer Sporttherapie. Monatsschrift Kinderheilkunde, 2021
90. Hopf, S.M., Wang, Q., Frias, C., Ahrweiler, M., Wilke, Ni., Wilke, Na., Berkessel, A., and Prokop, A.; A metal free salalen ligand with anti tumor and synergistic activity in resistant leukemia and solid tumor cells via mitochondrial pathway. Journal of Cancer Research and Clinical Oncology, 147(9): 2591–2607. 2021
91. Kater, L., Kater, B., Jakupec, M. A., Keppler, B. K., Prokop, A.; KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri. Journal of Biological Inorganic Chemistry, 26(8): 897–907. 2021
92. Schlagintweit, J. F., Jakob, C. H. G., Wilke, N. L., Ahrweiler, M., Frias, C., Frias, J., König, M., Esslinger, E.-M. H. J., Marques, F., Machado, J. F., Reich, R. M., Morais, T. S., Correia, J. o D. G., Prokop, A.*, and Kühn, F. E.*; Gold(I) Bis(1,2,3-triazol-5-ylidene) Complexes as Promising Selective Anticancer Compounds. Journal of medicinal Chemistry, 64, 21: 15747–15757. 2021
93. Stein, A., née Thomopoulou, P.H., Frias, C., Hopff, S.M., Varela, P., Wilke, Ni., Mariappan, A., Neudörfl, J.-M., Fedorov, A.Y., Gopalakrishnan, J., Gigant, B., Prokop, A.*, and Schmalz, H.-G.*; B nor-methylene Colchicinoid PT-100 selectively induces apoptosis in multidrug-resistant human cancer cells via an intrinsic pathway in a Caspase-independent manner. ACS Omega, 7: 2591−2603, 2022
94. Otten, S., Bischoff, C., Oschwald, V., Prokop, A., Maas, V., Bloch, W., Streckmann, F., Däggelmann, J.; Sensomotoriktraining in der Kinderonkologie – Umsetzung eines kindgerechten und spielerischen Trainingskonzepts. Bewegungstherapie und Gesundheitssport, 38: 30–35, 2022
95. Oschwald, V., Prokop, A., Streckmann, F., Bloch, W., Baumann, F., Däggelmann, J.;
Whole-body vibration training for inpatient children and adolescents receiving chemotherapy for first cancer diagnosis: an exploratory feasibility study. German Journal of Exercise and Sport Research, 30(4):341-349, 2022
96. Gauß, G., Kesting, S., Creutzig, U., Baumann, F., Boos, J., Dirksen, U., Eckert, K., Erschig, R., Hernáiz Driever, P., Menrath, I., Prokop, A., Schneider, D., Siaplaouras, J., Stalf, H., Streitbürger, A., Wiener, A., Wiskemann, J., Wittke, T., und Götte, M.; Neue AWMF S2k-Leitlinie „Bewegungsförderung und Bewegungstherapie in der pädiatrischen Onkologie“. Monatsschrift Kinderheilkunde, 170:548–550. 2022
97. Onambele, L. A., Hoffmann, N., Kater, L., Hemmersbach, L.,Neudörfl, J.-M., Sitnikov, N., Kater, B., Frias, C., Schmalz, H.-G., and Prokop, A.; An organometallic analogue of combretastatin A-4 and its apoptosis-inducing effects on lymphoma, leukemia and other tumor cells in vitro. RSC Medicinal Chemistry, 13: 1044-1051, 2022
98. Baas, J., Bieringer, S., Frias, C., Frias, J., Soehnchen, C., Urmann, C., Ritter, S., Riepl, H., and Prokop, A.; Dihydroxyquingdainone induces apoptosis in leukemia and lymphoma cells via the mitochondrial pathway in a Bcl-2- and Caspase-3- dependent manner and overcomes resistance to cytostatic drugs in vitro. Molecules, 27(15):5038. 2022
99. Penkert, J., Strüwe, F.J., Dutzmann, C.M., Doergeloh, B.B., Montellier, E., Freycon, C., Keymling, M., Schlemmer, H.-P., Sänger, B., Hoffmann, B., Gerasimov, T., Blattmann, C., Fetscher, S., Frühwald, M., Hettmer, S., Kordes, U., Ridola, V., Benninger, S.K., Mastronuzzi, A., Schott, S., Nees, J., Prokop, A., Redlich, A., Seidel, M.G., Zimmermann, S., Pajtler, K.W., Pfister, S.M., Hainaut, P., Kratz, C.P.; Genotype-Phenotype Associations within the Li-Fraumeni Spectrum – A Report from the German Registry. Journal of Hematology & Oncology, 15:107. 2022
100. Wilke, N, Abodo, O., Frias, C., Frias, J., Baas, J., Jakupec, M.A., Keppler, B.K., Prokop, A.; The gallium complex KP46 sensitizes resistant leukemia cells and overcomes Bcl-2-induced multidrug resistance in lymphoma cells via upregulation of Harakiri and downregulation of XIAP in vitro. Biomedicine & Pharmacotherapy, 156: 2022
Patente:
1. Prokop, A., Wieder, T., Daniel, P. T. and Schmalz, H-G.; Substances for use in therapy of diseases that are caused by highly proliferative cells.
7.4.2001, German patent DE, No. 10117479.9 (PRIO)
6.4.2002, PCT, No. WO 02/080923 A1
7.10.2003 PCT, No. 2002-578962
28.7.2004 JP,, US, EP, AT, CH, DE, FR, GB, IE, IT, SE, No. 02742877.0
2. Prokop, A., Wieder, T., Velcicky, J. and Schmalz, H-G.; New derivates of nucleosides inducing apoptosis for use in therapy of diseases that are caused by highly proliferative cells. 10.2.2003, German patent, No. DE 10305575.4
10.2.2004, PCT/EP04/01212
3. Prokop, A., Wieder, T. and Riepl, H.; Derivates of Tryptanthrine for use in therapy of diseases that are caused by highly proliferative cells.
4.4.2003, German patent, No. DE 10315654.2
1.4.2004, PCT/EP2004/003467
4. Prokop, A., Selig, A., Franke, D., Gansäuer, A.; Carbonyl-substituierte Titanocene, 17.11.2006, German patent DE 10 054 690.3-44 19.11.2007, PCT/EP2007/062511 19.11.2007, US 11/942,659
5. Prokop, A., Tatarskiy, V.; Kupfer-Organokomplexe, deren Verwendung als Antitumormittel und zum Schutz gesunden Gewebes vor ionisierender Strahlung, 22.2.2008, European patent No: EP 08 151 840.9
6. Sheshbaradaran H; Prokop A., Baerga R. Cobb J. Valiahdi M. S. Lee, S., Keppler B.; Method for treating hematological cancers; 09.05.2013 United States Patent US20130116225
7. Prokop, A., Schmalz, H.-G., Pharmaceutical composition for the therapy of diseases caused by highly proliferating cells. 2015, European Patent, PCT/EP2016/054538, 3.3.2016
8. Prokop, A., Baas, J., Taspinar, Ö., Wilczek, T., and Schmalz, H.-G.; Epoxysteroides for the therapy solid tumor, lymphoma and leukemia cells resistant to common cytostatic drugs. 2021, European Patent, PCT/EP2021/
Kurzveröffentlichungen/Poster:
1. Daniel, P.T., Prokop, A., Wieder, T., Sturm, I., Eßmann, F., Seeger, K., Wuchter, C.,
Ludwig, W.-D., Dörken, B., and Henze, G., Relapse in childhood acute lymphoblastic
leukemia is associated with a decrease of the Bax/Bcl-2- ratio and loss of spontaneous
caspase-3 processing in vivo, Blood, 2000
2. Lode, H.N., Huebener, N., Zeng, Y., Wrasidlo, W., Gaedicke, G., Henze, G., Wieder, T., Daniel, P.T., and Prokop, A., Treatment of CD19+ leukemia by targeted calicheamicin theta specifically eradicates Established disease, Blood, 2003, 102 (11), 621
3. Daniel, P.T., Müller, A., Belka, C., Prokop, A., Schulze-Osthoff, K. and Dörken, B.,
Mechanism of cell death induction by adenine deoxinucleosides fludarabine and cladribine:
Differential requirement of caspase-9,Blood, 2003, 102 (11), 592.
4. Lange, B., Prokop, A., Wieder, T., Schröder, U., Henze, G., Gaedicke, G., Zeng, Y.,
Huebener, N. Wrasidlo, W., Shabat, D. and Lode, H.N., Mechanisms of pro-VP-16-mediated
anti-tumor effects, Blood, 2003, 102 (11), 859
5. Prokop, A., Wieder, T., Schlawe, D., Lode, H., Henze, G., Daniel, P.T. and Schmalz,
H.G.,Iron containing nucleosides as new cytostatic substances for cancer and leukemia
therapy, especially for therapy of relapsed ALL in childhood, Blood, 2004, 104, 574
6. Tata, P.S., Prokop, A., Riepl, H., Kayser, O., Radam, E., Kropp, E. and Kiderlen,
A.F., In vitro efficacy of established and novel pharmaceutical agents against Balamuthia
mandrillaris ameba, 14. Japanese-German symposium on protozoan deseases, Düsseldorf,
Germany, 20.9. – 24.9.2004
7. Prokop, A., Bagci, B., Lingfeld, G., Badiali, L., Garbrecht, K., Mietzsch, U., Wieder, T., Daniel, P.T. and Henze, G. Sensitivity of Childhood Acute Lymphoblastic Leukemia (ALL) to Idarubicin Is Significantly Higher Than to Daunorubicin Treatment Based on Ex Vivo Apoptosis Induction. Blood; 104: 4495; 2004
8. Prokop, A., Frias, C., Henze, G., Sadolinnaya, S. and Tatarskiy, V. Copper-Complexed Melphalan (MOC*M), a Member of a New Class of Anti-Leukemic and Anti-Tumouric Substances for Treatment of Primary and Relapsed Acute Lymphoblastic Leukemia in Childhood. Blood, 106: 4457; 2005
9. Prokop, A., Bagci, B., Lingfeld, G., Badiali, L., Mietzsch, U., Wieder, T., Daniel, P.T. and Henze, G., Sensitivity of childhood acute lymphoblastic leukemia (ALL) to Idarubicin is significantly higher than to Daunorubicin treatment based on ex vivo apoptosis induction, 6 th Symposium of leukemia and lymphoma, Amsterdam, Netherlands, 2005
10. Seifert, G., Jesse, P., Laengler, A., Henze, G., Lode H. N., Prokop, A., Effective induction of apoptosis by Mistletoe plant extracts in an acute lymphoblastic leukemia model, Blood, 108: 1880; 2006
11. Prokop, A., Eissmann, M., Jesse, P., Henze, G., James, P., Neudoerfl, J., Schmalz, H.G. Ferrocenyl Nucleoside Analogs, a New Class of Cytostatic Drugs, Overcome Multiple Drug Resistance in Acute Lymphoplastic Leukemia Ex Vivo.� Blood, 108: 4404; 2006
12. Katik, B., Selig, A., Velder, J., Shults, E.E., Wieder, T., Henze, G., Schmalz, H.-G., Prokop, A., New Pinostilbene Analogues Overcome Anthracycline Resistance in Acute Lymphoplastic Leukemia Ex Vivo. Blood, 108: 4403; 2006
13. Selig, A., Wagner, L., Winkler, I., Lauterbach, T., Gansäuer, A. and Prokop, A., Carbonyl-substituted Titanocenes as new cytostatic agents against lymphoma and leukemia in childhood, Blood, 110: 4208; 2007
14. Jesse, P., Mottke, G., Fulda, S., Seifert, G., Henze, G. and Prokop, A., Apoptosis Induced by Extracts of Helleborus Niger in Different Lymphoma and Leukemia Cell Lines and Primary Lymphoblasts of Children with ALL Is Independent of Smac- Overexpression and Executed via the Mitochondrial Pathway, Blood, 110: 4215; 2007
15. Franke, J. C., Prokop, A., Schlawe, D., Hans-Günther Schmalz, H.-G., Fecker, L.F. and Eberle, J.. The new iron-containing nucleoside analogue N69 triggers apoptosis in human melanoma cells by a caspase-independent way, ADF, Frankfurt, 2007
16. Seifert, G., Jesse, P., Laengler, A., Lode, H.N., Prokop, A., Henze, G.: Therapeutische Wirksamkeit von Mistelextrakten in vitro und in vivo in einem Leukämiemodell durch Apoptoseinduktion. Mistletoe plant extracts have therapeutic activity against acute lymphoblastic leukemia in vitro and in vivo by induction of apoptosis. 4. Mistelsymposium, D66620 Nonnweiler, 9.11.2007
17. Seifert, G., Jesse, P., Längler, A., Henze, G., Prokop, A., Lode, H., Experimental therapeutic efficacy of mistletoe plant extracts in acute lymphoblastic leukemia, DKK, 2007
18. Prokop, A., Eissmann, M., Kater, B., Henze, G., Eberle, J., Geilen, C.C., Franke, J., James, P., Neudörfl, J., and Schmalz, H.G.; New pan-anti-tumor Ferrocenyl nucleoside analogues overcome multiple drug resistance in malignant cells in vitro and ex vivo. 1. ICDDD, Dubai, World Trade Center, 4.-7.2.2008
19. Prokop, A., Wagner, L., Selig, A., Kater, L., Winkler, I., Lauterbach, T., and Gansäuer, A.; Carbonyl-substituted Titanocenes, a new class of cytostatic agents against lymphoma and leukemia in childhood. 1. ICDDD, Dubai, World Trade Center, 4.-7.2.2008
20. Franke, J. C., Prokop, A., Schlawe, D., Hans-Günther Schmalz, H.-G. and Eberle, J. The iron-containing nucleoside analogue N69 induces apoptosis in human melanoma cells by a caspase-independent way and cytochrome c release, JCF, Luxemburg, 2008
21. Franke, J. C., Prokop, A., Schlawe, D., Hans-Günther Schmalz, H.-G. and Eberle, J.; The iron-containing nucleoside analogue N69 efficiently induces apoptosis in human melanoma cells by activating new pathways enclosing lysosomal activation, ADF, Erlangen, 2008
22. Prokop, A., Eissmann, M., Kater, B., Henze, G., Eberle, J., Geilen, C.C., James, P., and Schmalz, H.-G.; Ferrocenyl nucleoside analogues, a new class of pan-anti-tumor agents, overcome multiple drug resistance in malignant cells in vitro and ex vivo. Symposium on Medicinal Organometallic Chemistry (DFG), St. Martin, Germany, 2.5. – 5.5.2008
23. Prokop, A., Wagner, L., Selig, A., Kater, L., Winkler, I., Lauterbach, T., Gansäuer, A.; A new class of cytostatic agents: Carbonyl-substituted Titanocenes against lymphoma and leukemia in childhood; Symposium on Medicinal Organometallic Chemistry (DFG), St. Martin, Germany, 2.5. – 5.5.2008
24. Jesse, P., Mottke, G., Henze, G. and Prokop, A.; Apoptosis Induced by Helleborus Niger In Primary Cells of Children with ALL or AML And Different Cancer Cell Lines Is Executed via the Mitochondrial Pathway in Bcl-2 Dependent Manner. Jahrestagung der Gesellschaftanthroposophischer Ärzte, Kassel, Germany, 2.-6.4.2008
25. Jesse, P., Riepl, H., Wieder, T. and Prokop, A.; The Synthetic Analogue of Plant Colorant Tryptanthrin, NT1, Induces Apoptosis In Vitro, Ex Vivo and In Vivo in CD95Dependent Manner in Pediatric Leukemia and Lymphoma Sensitizing Malignant Cells against Cytostatic Drugs via Downregulation of XIAP, Blood, ASH San Francisco, 6.12.2008
26. Lee, S.-Y., Hille, A., Frias, C., Henze, G., Gust, R., Prokop, A.; New iron and nickel salophenes with anticancer activity ovecome drug resistance in malignant cells. DFG-Konferenz FOR 630, Kaiserslautern, 2009
27. Kater, B., Hunold, A., Schmalz, H.-G., Kater, L., Onambele, L., Bonitzki, B., Henze, G., Eberle, J., Prokop, A.; A novel Ferrocenyl analogue induces apoptosis in cancer cells and overcomes mechanisms of drug resistance. DFG-Konferenz FOR 630, Kaiserslautern, 2009
28. Onambele, L. A., Hoffmann, N., Schmalz, H.-G., Kater, L., Kater, B., Eberle, J., Prokop, A.; Effects of a novel apoptosis-inducing cobalt organo-complex on lymphoma, leukemia and melanoma cells in vitro. DFG-Konferenz FOR 630, Goslar, 2010
29. Lee, S.-Y., Hille, A., Frias, C., Kater, L., Kater, B., Gust, R., Prokop, A.; [FeIIIsalophene(Cl)], a novel iron salophene complex with high antitumor activity, induces apoptosis via the intrinsic pathway and overcomes drug resistance in malignant lymphoma and leukemia cells. DFG-Konferenz FOR 630, Goslar, 2010
30. Prokop, A., Zadolinnaya, S., Frias, C., Valeriy Tatarskiy, V.; A novel metal complex with potent antitumor activity in vivo and in human. ASCO, 2011, Chicago
31. Beulertz, J., Prokop, A., Zopf, E., Zimmer, P., Bloch, W., Baumann, F.T.; Establishment of a specific and individualized exercise program for children following intensive oncological treatment. European Review of Aging and Physical Activity; 2012
32. Beulertz, J., Bloch, W., Prokop, A., Baumann, F.T.; Einfluss eines zielgerichteten und individualisierten Sportprogramms auf die motorische Leistungsfähigkeit und gesundheitsbezogene Lebensqualität krebskranker Kinder und Jugendlicher – erste Ergebnisse. Monatsschrift Kinderheilkunde. 2013; 161.
33. Beulertz, J., Prokop, A., Zopf, E., Zimmer, P., Bloch, W., Baumann, F.T.; Establishment of a specific and individualized exercise program for children following intensive oncological treatment. Abstract. European Review of Aging and Physical Activity. 2013, 10: 66.
34. Oehninger, L., Spreckelmeyer, S., Holenya, P., Küster, N., Prokop, A., Wölfl, S., Ott, I.; Insights into the chemical biology of rhodium(I) N-heterocyclic carbene complexes as anticancer agents. International Symposium on Bioorganometallic Chemistry – ISBOMC
ISBOMC 2014, 22. – 25.7.2014 in Wien
35. Serebryanskaya, T., Ivashkevich, L. Lyakhov, A., Prokop, A., Ott, I. ; Tetrazole-based gold(I) complexes as a new group of anticancer agents. Trends in Inorganic Chemistry – TINC 2014, 22.5.2014 in Lund, Sweden
36. Schmidt, C., Misgeld, R., Prokop, A. and Ott, I.; Halogenated Gold(I) N-heterocyclic Carbene Complexes: Biodistribution, Cytotoxicity and Thioredoxin Reductase Inhibition. 13th International Symposium on Applied Bioinorganic Chemistry (ISABC), Galway, Ireland (12-15 June 2015)
37. Abodo Onambele, L., Riepl, H., Fischer, R., Pradel, G., Prokop, A., and Aminake, M. N.; Evaluation of antiplasmodial activity of tryptanthrin derivatives. 53th international congress of medicinal plants and natural product research, August 2015
38. Rustler, V., Baumann, F.T., Bloch1, W., Prokop, A. und Beulertz, J.; Einfluss einer 6-monatigen, gruppenbasierten Sportintervention auf die motorische Leistungsfähigkeit krebskranker Kinder und Jugendlicher nach stationärer, medizinischer Therapie. Deutsche Vereinigung der Sportwissenschaften-Hochschultag in Mainz, 30.9. – 2.10. 2015
39. Rustler, V., Prokop, A., Beulertz, J., Streckmann, F., Bloch, W., Baumann, F.T.; Feasibility and Effects of whole-body vibration training for inpatient childhood cancer patients undergoing chemotherapy: a protocol of the KiVi study. Deutsche Krebskongress in Berlin, 24. - 27. 2. 2016
40. Rustler, V., Prokop, A., Däggelmann, J., Streckmann, F., Harscheid, F. Gressler, N., Bloch, W., Baumann, F.T.; Vibrationstraining für onkologisch erkrankte Kinder und Jugendliche nach Abschluss der stationären Akuttherapie – Praxiserfahrungen. Netzwerktreffen ActiveOncoKids, Heidelberg, 8.–10.9. 2016
41. Lehnen, U., Kellner, M., Gottschlich, M., Prokop, A., Guggemos, A., Deckert, M., Stenzel, M.; Sinterungsfraktur eines singulären Brustwirbelkörpers als Erstmanifestation einer akuten lymphoblastischen Leukämie (ALL). GPR in Stuttgart, 15.–17.9. 2016
42. Rustler, V., Prokop, A., Bloch, W., Streckmann, F., Baumann, F., und Däggelmann, J.; Vibrationstraining als innovative Trainingsform für krebskranke Kinder und Jugendliche während der medizinischen Therapie. IMPULSE Wissenschaftdmagazin der Deutschen Sporthochschule Köln, 01/2017
43. Rustler, V., Prokop, A., Böhme, J., Scheiner, H., Gressler, N., Bloch, W.,1, Baumann, F.T., und Däggelmann, J.; Teilnahmequoten einer stationären Sporttherapie für krebskranke Kinder und Jugendliche unter Chemotherapie. Deutscher Olympischer Sportärztekongress DGSP in Hamburg, 05/2018
44. Stein, A., Thomopoulou, P., Schulte, T., Gigant, B., Prokop, A., Schmalz, H.-G.;
Adventures in the synthesis and biological evaluation of novel “reactive” Colchicine-derived compounds. ISCNP in Athen, 11/2018
45. Oschwald, V., Prokop, A., Otten, S., Maas, V., Streckmann, F., Bloch, W., Krumbach, J., Däggelmann, J.; Safety of a combined supervised and home-based whole-body vibration intervention for childhood cancer survivors. Deutscher Krebskongress in Berlin, 02/2020
46. Otten,S., Prokop, A., Oschwald, V., Maas, V., Streckmann, F., Bloch, W., Krumbach, J., Willibald, S., Däggelmann, J.; Effects of a whole-body vibration intervention in children and adolescents after inpatient anticancer therapy on ankle dorsiflexion function and balance control. Deutscher Krebskongress in Berlin, 02/2020
47. Gauß, G., Kesting, S., Basu, O., Baumann, F., Boos, J., Creutzig, U., Dirksen, U., Döring, S., Eckert, K., Erschig, R., Goebel, A.-M., Hernáiz Driever, P., Menrath, I., Prokop, A., Schneider, D., Siaplaouras, J., Stössel, S., Stalf, H., Streitbürger, A., Wiener, A., Wiskemann, J., Wittke, T., Götte, M.; Movement and Exercise Guideline in Pediatric Oncology – an AWMF-S2k guideline of the Network ActiveOncoKids, a working group of the GPOH. Deutscher Krebskongress in Berlin, 11/2022
48. Otten, S., Bischoff, C., Prokop, A., Maas, V., Bloch, W., Streckmann, F., Däggelmann, J., Oschwald, V.; Perceived exertion of sensorimotor training in childhood cancer survivors. Deutscher Krebskongress in Berlin, 11/2022
49. Riepl, H., Urmann, C., Bieringer, S., Ritter, S., Baas, J., Frias, C., Frias, J., Soehnchen, C., and Prokop, A.; Rare Isatis tinctoria metabolites: Quingdainones overcome multidrug resistance in leukemia cells in vitro. Jahrestagung der Gesellschaft für Arzneipflanzenforschung in Saloniki (Greece), 10/2022
50. Penkert, J., Strüwe, F.J., Dutzmann, C.M., Doergeloh, B.B., Montellier, E., Freycon, C., Keymling, M., Schlemmer, H.-P., Sänger, B., Hoffmann, B., Gerasimov, T., Blattmann, C., Fetscher, S., Frühwald, M., Hettmer, S., Kordes, U., Ridola, V., Benninger, S.K., Mastronuzzi, A., Schott, S., Nees, J., Prokop, A., Redlich, A., Seidel, M.G., Zimmermann, S., Pajtler, K.W., Pfister, S.M., Hainaut, P., Kratz, C.P.; Genotyp-Phänotyp Korrelationen innerhalb des Li-Fraumeni Spektrums. GPOH in Frankfurt, 11/2022